Collegium Pharma (COLL) Tops Q3 EPS by 9c

Collegium Pharma (NASDAQ: COLL) reported Q3 EPS of $1.34, $0.09 better than the analyst estimate of $1.25. Revenue for the quarter came in at $136.7 million versus the consensus estimate of $138.54 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• Solstice acquiring Element Solutions in $14.5B cash and stock deal
• Proto Labs (PRLB) PT Raised to $91 at Benchmark on Meeting and Exceeding Previous Target
• Solstice to acquire Element Solutions in $14.5B deal